BroderS: Pharmacodynamics of 2′,3′-dideoxycytidine: An inhibitor of human immunodeficiency virus. Am J Med88:5B/2S–7S, 1990.
2.
WhittingtonRBrogdenRN: Zalcitabine: A review of its pharmacology and clinical potential in acquired immunodeficiency syndrome [AIDS]. Drugs44:656–683, 1992.
3.
LipskyJJ: Zalcitabine and didanosine. Lancet.341:30–32, 1993.
4.
MeriganTCSkowronGBozzetteSA: Circulating p24 antigen levels and responses to dideoxycytidine in human immunodeficiency virus [HIV] infections: A Phase I and II study. Ann Intern Med110:189–194, 1989.
5.
YarchoanRThomasRVAllainJP: Phase I studies of 2′,3′-dideoxycytidine in severe human immunodeficiency virus infection as a single agent and alternating with zidovudine [AZT]. Lancet1:76–80, 1988.
6.
BergerARArezzoJCSchaumburgHH: 2′,3′-Dideoxycytidine [ddC] toxic neuropathy: A study of 52 patients. Neurology43:358–362, 1993.
7.
MengTCFischlMABootaAM: Combination therapy with zidovudine and dideoxycytidine in patients with advanced human immunodeficiency virus infection. Ann Intern Med116:13–19, 1992.
8.
SkowronGBozetteSALimL: Alternating and intermittent regimens of zidovudine and dideoxycytidine in patients with AIDS or AIDS-related complex. Ann Intern Med118:321–330, 1993.
9.
MatthewsSJCersosimaRJSpivackML: Zidovudine and other reverse transcriptase inhibitors in the management of human immunodeficiency virus-related disease. Pharmacotherapy11:419–449, 1991.
10.
DubinskyRMYarchoanRDalakasMBroderS: Reversible axonal neuropathy from the treatment of AIDS and related disorders with 2′,3′-dideoxycytidine [ddC]. Muscle Nerve.12:856–860, 1989.
11.
SimpsonDMOlneyRK: Peripheral neuropathies associated with human immunodeficiency virus infection. Neurol Clin10:685–711, 1992.
